Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”) is a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences industry. Our products/services are based on three patented, pressure-based platforms: (i) Pressure Cycling Technology (“PCT”), (ii) Pressure Enabled Protein Manufacturing Technology (“PreEMT”), and (iii) Ultra Shear Technology (“UST”). We have over 300 instruments placed in approximately 200 sites worldwide, there are over 120 publications that speak to the advantages of our three unique platform technologies, and we reported sales of over $2.2 million in 2017.
The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction), the PCT Platform is used by laboratories worldwide in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. The PreEMT Platform can be used to significantly impact and improve the quality of protein therapeutics, this unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water...such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble.